FBXO44 Activators
FGL1 Activators can be grouped into three categories. The first group includes compounds that influence cGMP levels, such as L-Arginine, Sildenafil, BAY 63-2521, and 8-Bromo-cGMP. L-Arginine is a substrate for nitric oxide synthase (NOS), which produces nitric oxide (NO). NO activates guanylate cyclase, leading to increased cGMP levels, which can enhance FGL1 function. Sildenafil, a PDE5 inhibitor, and BAY 63-2521, a guanylate cyclase stimulator, also increase cGMP levels. 8-Bromo-cGMP, acell-permeable cGMP analogue, directly activates cGMP-dependent signaling pathways, which FGL1 is known to be involved in.
The second group contains compounds that affect cAMP levels, such as Forskolin, Rolipram, Cilostazol, Dibutyryl-cAMP, Isoproterenol, and Adenosine. Forskolin activates adenylyl cyclase, leading to an increase in cAMP levels, which can enhance FGL1 function. Rolipram and Cilostazol are inhibitors of PDE4 and PDE3, respectively, both of which degrade cAMP. By inhibiting these enzymes, cAMP levels increase, potentially enhancing FGL1's function. Dibutyryl-cAMP and Isoproterenol also increase cAMP levels, the former being a cell-permeable cAMP analogue and the latter being a non-selective beta-adrenergic agonist. Adenosine activates A2A receptors, leading to increased cAMP levels. The third group includes Acetylcholine and Histamine, which activate phospholipase C (PLC) through different receptors. PLC production leads to the creation of inositol trisphosphate (IP3) and diacylglycerol (DAG), enhancing FGL1 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a substrate for nitric oxide synthase (NOS), which produces nitric oxide (NO). NO can activate guanylate cyclase, leading to increased cGMP levels. Elevated cGMP levels can enhance FGL1 function, as it plays a role in activating cGMP-dependent signaling pathways. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to an increase in cAMP levels. FGL1's function is enhanced by cAMP-dependent signaling, as it is involved in these signaling pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), an enzyme that degrades cAMP. By inhibiting PDE4, rolipram increases cAMP levels, potentially enhancing FGL1's function, which is known to activate cAMP-dependent signaling pathways. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol is a selective inhibitor of phosphodiesterase 3 (PDE3), an enzyme that degrades cAMP. By inhibiting PDE3, cilostazol increases cAMP levels, potentially enhancing FGL1's function, which is known to activate cAMP-dependent signaling pathways. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
BAY 63-2521 is a soluble guanylate cyclase stimulator. By stimulating guanylate cyclase, BAY 63-2521 increases cGMP levels, potentially enhancing FGL1's function, which is known to activate cGMP-dependent signaling pathways. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analogue. It can activate cAMP-dependent signaling pathways, potentially enhancing FGL1's function, which is known to be involved in these pathways. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can activate H1 receptors coupled to G proteins that activate phospholipase C (PLC). This leads to the production of inositol trisphosphate (IP3) and diacylglycerol (DAG), which can enhance FGL1 function as it is involved in IP3 and DAG-mediated signaling pathways. | ||||||
8-Bromo-cGMP | 51116-01-9 | sc-200316 sc-200316A | 10 mg 50 mg | $104.00 $354.00 | 7 | |
8-Bromo-cGMP is a cell-permeable cGMP analogue. It can activate cGMP-dependent signaling pathways, potentially enhancing FGL1's function, which is known to be involved in these pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a non-selective beta-adrenergic agonist. It can increase intracellular cAMP levels, potentially enhancing FGL1's function, which is known to activate cAMP-dependent signaling pathways. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine can activate A2A receptors, which are coupled to G proteins that activate adenylyl cyclase, leading to increased cAMP levels. Higher cAMP levels can enhance FGL1 function, as it plays a role in activating cAMP-dependent signaling pathways. | ||||||